ArticleGenetics2025
Transcriptional control of C. elegans male tail tip morphogenesis by DMD-3.
Article in Genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A panoramic view of the expression and function of the Doublesex/DMRT gene family inScience advances · 2026Article
- Developmental constraints in the repeated evolution of male tail characters in rhabditid and diplogastrid nematodes.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sexually dimorphic morphogenesis is governed by DM-domain transcription factors (TFs) in many animals, but how this transcriptional control links to the morphogenetic mechanisms is insufficiently known. The DM-domain TF DMD-3 in Caenorhabditis elegans is the master regulator of a male-specific morphogenetic event that changes the shape of the tail tip from long and pointed in larvae to short and round in adults. This tail tip morphogenesis (TTM) involves cell-shape changes, cell migration, and fusion. To understand how transcriptional regulation by DMD-3 governs TTM, we used male-specific ChIP-seq to identify its direct targets. We found 1,755 DMD-3-bound sites. We identify a DMD-3-associated binding motif and validate its function in TTM. This motif is similar to the binding motif of EOR-1, and eor-1 mutations affect TTM at a penetrance of 13%. This suggests that DMD-3 may act cooperatively with EOR-1 and possibly other TFs. DMD-3 targets 273 genes that play a role in TTM. These genes include other TFs as well as effectors and components of morphogenetic mechanisms. By deleting DMD-3-bound sites endogenously and observing changes in reporter expression and tail tip phenotypes, we identify tissue-specific enhancers in the cis-regulatory regions of fos-1, pan-1, nmy-2, and hmr-1 that play a role in TTM. For fos-1, we propose that a feed-forward loop is responsible for the tail-tip-specific increase in gene expression. Our study suggests that the gene regulatory network for TTM downstream of DMD-3 involves an unexpectedly large hierarchical cascade of TFs, but DMD-3 directly targets some non-TF genes as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.